This document lists 29 references related to research on monoclonal antibodies and cytokines in asthma treatment. It discusses studies on the effects of omalizumab (anti-IgE) therapy on circulating cytokine levels in asthma-COPD overlap syndrome and its use in treating levofloxacin induced toxic epidermal necrolysis. It also reviews the role of humanized monoclonal antibodies in asthma therapy and whether anti-IgE treatment increases infection risk. Finally, it provides background on the adipokines chemerin and irisin which are increased in severe persistent allergic asthma and notes irisin is a 112 amino acid protein and chemerin a 163 amino acid precursor involved in immune cell chemotaxis. The document is authored by

4.  22.Yalcin AD, Celik B,Yalcin AN. Omalizumab (anti-IgE) therapy in the asthma-COPD
overlap syndrome (ACOS) and its effects on circulating cytokine
levels.Immunopharmacol Immunotoxicol. 2016 Jun;38(3):253-6. doi:
10.3109/08923973.2016.1173057.
 23. Uzun R,Yalcin AD, Celik B, BulutT,Yalcin AN. Levofloxacin InducedToxic Epidermal
Necrolysis: SuccessfulTherapy with Omalizumab (Anti-IgE) and Pulse Prednisolone.Am J
Case Rep. 2016 Sep 16;17:666-71.
 24.Yalcin AD. Human(ized) Monoclonal Antibodies in Asthma: Future Perspectives.
.Editorial. J AllergyTher 7:e115. doi:10.4172/2155-6121.1000e115.
 25. Aydın GÇ, Arslan E,Yalcin AD. Does the Anti-Immunoglobulin E (Anti-IgE)Treatment
Increase the Risk of Infection? Canadian Respiratory Journal 2017 in press.
 26.Yalcin AD. BiologicalAgents in Asthma therapy: An Overview.Editorial. Canadian
Respiratory Journal 2017 in press.
 27. Onbaşı KT, Yalcin AD. Human(ized) Monoclonal Antibodies in Asthma. Canadian
Respiratory Journal 2017 in press.
 28. BulutT, Uzun R, Gunal O, Yalcin AD. Anti-IgE Monoclonal Antibody in Bronchiectasis:
New Perspective . Canadian Respiratory Journal 2017 in press.

5. 29. CIRCULATING ADIPOKINE
CHEMERIN, IRISIN AND IL-1Β
LEVELS WERE INCREASED IN SEVERE
PERSISTENT ALLERGIC ASTHMA
PATIENTS

8.  Iris (Greek mythology) . Boström and
colleagues reported increased fibronectin
type III domain-containing protein 5 (FNDC5).
112 amino acids and molecular weight of 12
kDa

11.  Chemerin’s mRNA is identified at high levels
in the lung, kidney, colon, skin and liver.
Chemerin was originally recognized as a
chemoattractant protein mainly mediating
the chemotaxis of plasmacytoid dendritic
cells(CD80) and natural killer cells
(NKC,CD16,CD56). 163 amino acid precursor
(pro-chemerin)

16. Prof. Dr. Tse Wen Chang

17. adidyal@yahoo.com
https://www.researchgate.net/profile/Arzu_Yalcin